Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.48 |
| ▸ | PDE4A | P27815 | 9/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709606 | 0.99 | EPHX2 (0.52) | EPHX2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3773452 | 0.81 | TOP2A (0.44) | EPHX2SLC5A7CYP3A4IDO1 | |
| SCHEMBL712198 | 0.79 | SSTR4 (0.46) | EPHX2CYP3A4IDO1 | |
| SCHEMBL15967240 | 0.77 | KCNH2 (0.47) | CYP3A4IDO1SLC6A9 | |
| SCHEMBL712172 | 0.77 | RECQL (0.43) | EPHX2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL709607 | 0.76 | RECQL (0.42) | EPHX2PDE4BCYP3A4SLC6A9SLC6A5 | |
| Hydrochloric Acid SCHEMBL709864 | 0.76 | KCNH2 (0.46) | CYP3A4IDO1SLC6A9 | |
| SCHEMBL708326 | 0.75 | TAS1R3 (0.50) | EPHX2CYP3A4IDO1SLC6A9SLC6A5 | |
| Hydrochloric Acid SCHEMBL711109 | 0.74 | TAS1R3 (0.49) | EPHX2CYP3A4IDO1SLC6A9SLC6A5 | |
| SCHEMBL1409590 | 0.74 | PDE4D (0.53) | EPHX2PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8124639-B2 | Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | EPHX2 3016/4885PDE4D 3476/4885PDE4A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.